AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease | Region eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
TakedaTSE4502NYSETAK today announced positive topline results from a Phase 2 randomized doubleblind placebocontrolled study evaluating the safety tolerability and efficacy of mezagitamab TAK079 in patients with persistent or chronic primary immune thrombocytopenia ITP.
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.